Saturday 17 October 2026
Export DXR’s income statement to Excel — free account
Daxor Corporation
DXR Healthcare Medical Instruments & Supplies
Revenue growth for five consecutive years.
10.05
0.15
−1.47%
Follow DXR
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Trend | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 7.00 | 4.04 | 3.40 | 7.13 | 7.85 | 8.58 | 8.84 |
Analyst estimates 2023–2025 Powerpack |
|||
| High | — | — | — | 9.80 | 9.20 | 21.66 | 19.95 | 24.08 | 17.58 | 14.55 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 1 | — | — | 2 | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EBT | — | — | — | 1 | (1) | (1) | 0 | (2) | 5 | 5 | |||||
| EBT margin, % | — | — | — | 219.67 | 83.18 | 93.16 | (28.47) | 61.67 | (181.56) | (1,465.22) | |||||
| Net income | — | — | — | 1 | (1) | (1) | 0 | (2) | 5 | 5 | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.17 | (0.39) | (0.35) | 0.46 | (0.71) | (0.65) | (0.09) | ||||
| Earnings | — | — | — | 0.38 | (0.33) | (0.24) | (0.13) | (0.43) | 1.18 | 1.27 | |||||
| Cash flow | — | — | — | 0.35 | (0.60) | (0.35) | (0.55) | (0.72) | (0.70) | (0.85) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | 0.35 | (0.60) | (0.35) | (0.55) | (0.72) | (0.70) | (0.85) | |||||
| Book value | — | — | — | 4.01 | 3.65 | 3.49 | 3.41 | 3.98 | 5.24 | 7.09 | |||||
| Shares, m | — | — | — | 4 | 4 | 4 | 4 | 4 | 4 | 4 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.68 | 3.67 | ||||
| P/S | — | — | — | 24.80 | 12.90 | 0.00 | 82.18 | 0.00 | 0.00 | 0.00 | |||||
| P/B | — | — | — | 0.99 | 0.52 | 2.35 | 2.76 | 3.22 | 2.15 | 1.27 | |||||
| EV/Sales | — | — | — | 7.08 | (4.82) | (58.90) | 85.27 | (49.34) | (9.35) | (13.47) | |||||
| EV/FCF | — | — | — | (1.54) | 1.05 | (12.05) | (10.77) | (10.79) | (8.97) | (6.35) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 1 | (2) | (1) | (2) | (3) | (3) | (3) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | 1 | (2) | (1) | (2) | (3) | (3) | (3) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | ||||
| Total debt | — | — | — | 3 | 4 | 4 | 1 | 0 | 3 | 1 | |||||
| Net debt | — | — | — | 1 | 3 | 4 | 1 | 0 | 2 | 1 | |||||
| Shareholders’ equity | — | — | — | 15 | 14 | 13 | 13 | 16 | 21 | 29 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 7.01 | (6.21) | (4.80) | (3.11) | (11.09) | 22.86 | 18.75 | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 9.78 | (8.52) | (6.61) | (3.84) | (11.99) | 25.79 | 20.66 | |||||
Negative figures in brackets.
value withheld pending a data check
Fiscal years to Dec 2022 · latest quarter Jun 2023
Charts ten years each
Daxor Corporation vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NYXH Nyxoah SA | $121.2M | — (loss-making) | — (loss-making) | +486.62% (above 0%: growing) | n/m | +4.01% (above 0%: growing) | 59.73% | (268.25%) | Compare |
| STXS Stereotaxis Inc. | $105.2M | — (loss-making) | — (loss-making) | −12.82% (below 0%: shrinking) | n/m | +0.45% (above 0%: growing) | 58.49% | (59.56%) | Compare |
| MBOT Microbot Medical Inc. | $63.8M | — (loss-making) | — | +1,047.62% (above 0%: growing) | n/m | −98.72% (below 0%: shrinking) | (266.80%) | (2,567.63%) | Compare |
| ZTEKF Zentek Ltd. | $62.3M | — (loss-making) | — | −95.36% (below 0%: shrinking) | n/m | −254.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DXR Daxor Corporation | $59.6M | 4.7× | 7.6× | −27.62% (below 0%: shrinking) | n/m | −88.56% (below 0%: shrinking) | 0.00% | 0.00% | |
| POCI Precision Optics Corp. | $47.7M | — (loss-making) | — | +41.95% (above 0%: growing) | n/m | −45.64% (below 0%: shrinking) | 25.34% | (1.21%) | Compare |
| NEPH Nephros Inc. | $38.1M | 23.4× | 76.0× | +36.16% (above 0%: growing) | +450.00% (above 0%: growing) | −31.49% (below 0%: shrinking) | 66.91% | 20.16% | Compare |
| HBIO Harvard Bioscience, Inc. | $37.8M | — (loss-making) | — (loss-making) | +11.13% (above 0%: growing) | n/m | −123.43% (below 0%: shrinking) | 55.57% | (4.30%) | Compare |
| MLSS Milestone Scientific, Inc. | $29.6M | — (loss-making) | — (loss-making) | +22.27% (above 0%: growing) | n/m | +66.68% (above 0%: growing) | 67.24% | (37.37%) | Compare |
| Median of peers | $55.0M | — | — | +29.22% | — | −38.56% | 57.03% | (20.83%) |
Daxor Corporation (DXR) key facts
- Daxor Corporation (DXR) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- Net income was $5.2 million, or $1.27 per share (basic), a net margin of −1,465.2%.
- As of October 16, 2026, DXR traded at $10.05, a market capitalization of $59.6 million.
- At that price the stock trades at 4.7× trailing-twelve-month earnings; its P/E is higher than 56% of its own readings over the past ten years.
- Return on equity was 20.7% and debt-to-equity 0.00.